Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

v3.20.2
Stockholders' Equity
6 Months Ended
Jun. 30, 2020
Stockholders' Equity Note [Abstract]  
Stockholders' Equity

Note 8. Stockholders’ Equity


Common Stock


Authorized Shares


The Company has 45,000,000 common shares authorized with a par value of $0.001 per share.


Issuance of Shares Pursuant to Conversion of Series A Preferred Stock


During January 2020, the Company issued 5,264 shares of common stock to a holder of its Series A Convertible Preferred Stock upon the conversion of 2,000 of such shares of Series A Convertible Preferred Stock.


During February 2020, the Company issued an aggregate of 172,369 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 65,500 of such shares of Series A Convertible Preferred Stock.


During April 2020, the Company issued an aggregate of 1,043,935 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 396,695 of such shares of Series A Convertible Preferred Stock.


During May 2020, the Company issued an aggregate of 51,316 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 19,500 of such shares of Series A Convertible Preferred Stock.


Issuance of Shares to Current and Former Employees and Directors


On January 8, 2020, the Company issued 50,000 shares of common stock to a former employee per the terms of a settlement agreement. 


On March 12, 2020, the Company issued 16,667 shares of common stock to an employee pursuant to a vesting schedule.


On April 15, 2020, the Company issued 3,913 shares of common stock to an employee pursuant to a vesting schedule.


On April 16, 2020, the Company issued 5,264 shares of common stock to a director pursuant to a vesting schedule.


On April 21, 2020, the Company issued 30,303 shares of common stock to a former employee pursuant to a vesting schedule. 


On June 24, 2020, the Company issued 25,000 shares of common stock to an employee pursuant to a vesting schedule.


Issuance of Shares Pursuant to Exercises of Common Stock Warrants


On April 14, 2020, a holder of common stock warrants exercised 7,000 warrants for a cash payment of $38,570.


Issuance of Shares Pursuant to Cashless Exercises of Common Stock Warrants


During April 2020, holders of common stock warrants exercised an aggregate of 520,925 warrants using a cashless exercise into 321,155 shares of common stock.


During May 2020, holders of common stock warrants exercised an aggregate of 56,982 warrants using a cashless exercise into 26,034 shares of common stock.


Issuance of Shares Pursuant to Cashless Exercises of Stock Options


During April 2020, holders of common stock options exercised an aggregate of 105,028 options using a cashless exercise into 57,534 shares of common stock.


Issuance of Shares Pursuant to Settlement of Accounts Payable


On April 16, 2020, the Company issued 100,000 shares of common stock in full settlement of $640,517 of accounts payable. The shares had a fair value of $6.95 per shares.


On May 12, 2020, the Company issued 104,567 shares of common stock in full settlement of $93,150 of accounts payable. The shares had a fair value of $5.76 per shares.


On June 24, 2020, the Company issued 80,000 shares of common stock and warrants to purchase 100,000 shares of common stock, of which 50,000 shall be exercisable at $3.80 per share and the remaining 50,000 shall be exercisable at $5.80 per share, in each case for a term of 5 years, in connection with the termination of a consulting arrangement and in full settlement of any and all claims again the Company. The Company had previously accrued $195,000 in connection with this consulting arrangement. The stock had a fair value of $5.76 per share.


Equity Financing


During May 2020, the Company received $515,000 of a committed $565,000 from the sale of 135,527 shares of common stock (at a price of $3.80 per share) and warrants to purchase 169,409 shares of common stock, at an exercise price of $4.00 per share. As of June 30, 2020, the full amount has not been received and the shares have not been issued. The $515,000 received through June 30, 2020 is included in equity financing within current liabilities on the unaudited condensed consolidated balance sheet.


Stock Incentive Plan 


The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the six months ended June 30, 2020 were:


    Warrant Grants     Stock Option Grants     Restricted Stock Units  
    Number of shares subject to warrants     Weighted-
average exercise price per share
    Number of shares subject to options     Weighted-
average exercise price per share
    Number of shares subject to restricted stock units     Weighted-
average exercise price per share
 
Balance at December 31, 2019     1,311,916     $ 8.80       338,595     $ 3.94       630,303     $            -  
Granted     100,000       4.80       -       -       2,300,845       -  
Exercised     (584,907 )     5.70       (105,028 )     4.28       (41,667 )     -  
Cancelled/Forfeited     -       -       -       -       (475,000 )     -  
Balance at June 30, 2020     827,009     $ 10.51       233,567     $ 7.16       2,414,481     $ -  
Exercisable at June 30, 2020     827,009     $ 10.51       233,567     $ 7.16       189,500     $ -  

As of June 30, 2020 and December 31, 2019, the total unrecognized expense for unvested stock options and restricted stock awards, net of actual forfeitures, was $3,885,115 and $3,236,292, respectively, to be recognized over a one to three year period for restricted stock awards and one year for option grants from the date of grant. 


Stock-based compensation expense for the three and six months ended June 30, 2020 and 2019 was as follows:


    For the three months ended     For the six months ended  
    June 30,     June 30,  
    2020     2019     2020     2019  
Stock-based compensation expense   $ 1,988,883     $ 220,540     $ 2,356,547     $ 5,850,373  

Stock-based compensation expense categorized by the equity components for the three and six months ended June 30, 2020 and 2019 was as follows:


    For the three months ended     For the six months ended  
    June 30,     June 30,  
    2020     2019     2020     2019  
Common stock   $ 1,988,883     $ 147,012     $ 2,356,416     $ 404,896  
Stock option awards     -       73,528       -       122,547  
Transfer of common stock by founders to contractors     -       -       -       5,322,930  
Total   $ 1,988,883     $ 220,540     $ 2,356,416     $ 5,850,373